Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
The PLUMMB study explores a new way to treat bladder cancer that has either grown into the muscle or spread to other parts of the body. It combines a drug called pembrolizumab, which helps your immune system fight cancer, with radiotherapy. The study will check how safe and effective this combination is, and compare two different doses of pembrolizumab. Patients will be split into two groups: those with advanced bladder cancer that hasn't spread far (Group A) and those whose cancer has spread (Group B). We want to understand if this treatment can help control the cancer, and what effects it might have on patients.
A colpo d'occhio
Di cosa tratta questo studio?
The PLUMMB study is looking into a new treatment for bladder cancer. This treatment involves using a drug called pembrolizumab, which is an 'immunotherapy'. Immunotherapy works by boosting your body's own immune system to recognise and fight cancer cells. This drug will be given alongside radiotherapy, which uses high-energy rays to kill cancer cells.
This is an early-stage study (called a 'Phase I trial'), which means we're carefully checking how safe the combination of pembrolizumab and radiotherapy is, and whether it has any effect on the cancer. We're also comparing two different amounts (doses) of pembrolizumab to see if one works better or has fewer side effects. We want to find the safest and most effective way to combine these treatments.
Patients taking part will have either bladder cancer that has grown into the muscle wall (locally advanced) or bladder cancer that has spread to other parts of the body (metastatic). This type of bladder cancer can be difficult to treat with standard methods, so we hope this new combination could offer another option. It's important to remember that because this is an early study, we don't yet know if this new treatment will be better than current treatments for everyone.
Punti chiave
- Tests a new combination treatment: immunotherapy (pembrolizumab) + radiotherapy.
- For bladder cancer that's grown into the muscle or spread.
- Early study to check safety and effectiveness.
- Compares two different doses of pembrolizumab.
- Involves regular hospital visits and check-ups.
- Patients can choose to leave the study at any time.
Chi può essere idoneo?
To join this study, your doctor will need to check some things. You must have bladder cancer that has grown into the muscle or spread to other parts of your body. You also need to be at least 18 years old and generally well enough to take part, as measured by your doctor.
There are also some things that would mean you can't join. For example, if you've recently taken part in another research study involving a new drug or device, or if you've had radiotherapy to your pelvic area before. Your care team will go through all the details with you to see if this study is right for you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Do I have bladder cancer that has invaded the muscle or spread?
- Am I aged 18 or older?
- Am I generally well enough to take part in a study?
- Have I recently participated in another trial involving a new drug or device? (If so, you might not be eligible).
- Have I had radiotherapy to my pelvic area in the past? (If so, you might not be eligible).
Cosa comporta la partecipazione?
If you join the study, you'll start with a dose of pembrolizumab two weeks before your radiotherapy begins. Your radiotherapy will last about 4 to 6 weeks. You'll continue to receive pembrolizumab every three weeks during and after radiotherapy.
If you have advanced bladder cancer that hasn't spread widely (Group A), you'll continue pembrolizumab for up to a year, unless your cancer gets worse or you have side effects that are too difficult to manage. If your cancer has spread (Group B), you'll continue pembrolizumab for as long as it's helping and you're not having severe side effects. You'll have hospital visits every three weeks during treatment, and then every 3-6 months afterwards. You'll also have CT scans throughout the study, and if you're in Group A, a camera test into your bladder (cystoscopy) three months after radiotherapy, which is standard care.
Rischi e benefici potenziali
Luoghi (1)
- NIHR Biomedical Research Centre at RM and ICR (https://www.cancerbrc.org/)Codice postale verificatoSutton, United Kingdom
Domande comuni
What is Pembrolizumab?
It's a type of medicine called immunotherapy that helps your body’s immune system fight cancer cells.
What does 'Phase I trial' mean?
It means this is an early study primarily focused on checking the safety and side effects of a new treatment, and seeing if it has any early signs of helping.
Will I still get regular radiotherapy?
Yes, all patients in the study will also receive the standard radiotherapy treatment.
How often will I need to visit the hospital?
You'll have hospital visits every three weeks during treatment, and then every 3-6 months afterwards for follow-up.
Posso smettere di partecipare allo studio se lo desidero?
Yes, you can leave the study at any time, for any reason, and it won't affect your future medical care.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.